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Summary  Patient  selection  plays  a  crucial  role  in  the  success  of  transcatheter  aortic  valve
implantation  (TAVI).  It  requires  meticulous  attention  to  the  smallest  of  details  and  needs  to  be
performed  in  a  systematic  manner  for  every  patient.  In  essence,  the  patient  must  be  assessed
from  access  to  implantation  site.  Becoming  over  ‘‘complacent’’  and  ‘‘routine’’  may  lead  to
failure  and  impact  patient  safety.  TAVI  is  indicated  for  high  or  prohibitive  surgical  risk  patients
with  severe  aortic  stenosis.  Some  patients,  however,  are  too  high  risk  even  for  TAVI.  In  addition
to  patient  risk  evaluation,  anatomical  selection  criteria  need  to  be  considered.  Multimodal-
ity  imaging,  using  a  combination  of  angiography,  echocardiography  and  multislice  computed
tomography,  is  necessary  to  determine  the  anatomical  suitability  for  the  procedure.
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Résumé  La  sélection  des  patients  joue  un  rôle  majeur  dans  le  succès  des  implantations  de
valve  aortique  par  voie  percutanée.  Elle  nécessite  de  porter  une  attention  méticuleuse  au  moin-
dre  détail  et  doit  être  réalisée  de  fac¸on  systématique  chez  chaque  patient.  Le  patient  doit  être
évalué  du  site  d’abord  à  la  valve  aortique.  Un  bilan  « complacent  » ?  (je  ne  sait  pas  le  traduire)
ou  trop  « routinier  » peut  conduire  à  l’échec  du  geste  et  entraîner  des  complications.  Les  valves
aortiques  percutanées  sont  indiquées  chez  les  patients  porteurs  d’un  rétrécissement  aortique
serré  et  considérés  comme  étant  à  risque  chirurgical  trop  élevé,  voire  même  contre-indiqués.
Certains  patients  peuvent  également  être  à  risque  trop  élevé  pour  une  valve  percutanée.  À
l’évaluation  du  risque  opératoire  doit  s’ajouter  l’évaluation  anatomique  du  patient.  Diverses
modalités  d’imagerie  telles  que  l’angiographie,  l’échographie  et  le  scanner,  sont  nécessaires
pour  évaluer  la  faisabilité  technique  du  geste.
©  2012  Elsevier  Masson  SAS.  Tous  droits  réservés.
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atient  selection  plays  a  crucial  role  in  the  success  of
ranscatheter aortic  valve  implantation  (TAVI).  It  requires
eticulous attention  to  the  smallest  of  details  and  needs
o be  performed  in  a  systematic  manner  for  every  patient.
n essence,  the  patient  must  be  assessed  from  access
o implantation  site.  Becoming  over  ‘‘complacent’’  and
‘routine’’ may  lead  to  failure  and  impact  patient  safety.
In  Europe,  TAVI  is  indicated  for  high  or  prohibitive  surgi-
al risk  patients  with  severe  aortic  stenosis.  Some  patients,
owever, are  too  high  risk  even  for  TAVI.  In  addition  to
atient risk  evaluation,  anatomical  selection  criteria  need
o be  considered.  Multimodality  imaging,  using  a  com-
ination of  angiography,  echocardiography  and  multislice
omputed tomography  (MSCT),  is  necessary  to  determine
he anatomical  suitability  for  the  procedure.  In  particular,
ssessment of  the  peripheral  vasculature  and  aortic  valvar
omplex will  allow  selection  of  the  access  route  and  pros-
hesis type  and  size,  respectively.
atient risk evaluation
 number  of  cardiac  surgical  risk  algorithms  have  been
eveloped over  the  last  20  years.  Despite  their  known  lim-
tations, the  logistic  EuroSCORE  I  and  the  STS  (Society  of
horacic Surgeons)  Predicted  Risk  of  Mortality  score  have
uided enrolment  of  ‘‘high  surgical  risk’’  patients  into  TAVI
rials.  Because  low-to-intermediate  surgical  risk  patients
haracterized the  development  of  these  risk  models,  their
eliability when  applied  to  high  or  prohibitive  surgical
isk patients  has  been  rightfully  questioned.  Furthermore,
odels may  not  take  into  account  important  comorbidities
e.g. porcelain  aorta,  chest  wall  radiation,  liver  cirrho-
is, pulmonary  hypertension)  and  frailty  variables  that
ay impact  clinical  outcomes.  The  newly  updated  logis-
ic EuroSCORE  II  and  STS  score,  however,  are  expected  to
ncorporate frailty  variables.
In  high  surgical  risk  patients,  the  logistic  EuroSCORE  I
ends to  overestimate  the  observed  mortality  risk  by  a  factor
f 2  to  3;  the  new  logistic  EuroSCORE  II  appears  to  pro-
ide signiﬁcantly  lower  mortality  estimates  than  the  logistic
uroSCORE I.  The  STS  score  has  been  found  to  be  more  reli-
t
t
c
fble  than  the  logistic  EuroSCORE  I  or  the  Ambler  Risk  Score
or the  prediction  of  operative  and  long-term  mortality  in
igh-risk patients  undergoing  surgical  aortic  valve  replace-
ent.
Clinical judgment  should  supersede  any  surgical  risk  algo-
ithm. Risk  scores  should  guide  but  not  dictate  clinical
ecision-making.
 need for a transcatheter aortic valve
mplantation  (TAVI) risk score?
 TAVI  risk  score  for  TAVI  patients,  akin  to  the  logistic
uroSCORE or  STS  score  for  surgical  patients,  is  currently
ot available.  A  TAVI  risk  score  may  provide  additional
nformation during  the  preprocedural  screening  process  to
etter understand  the  potential  outcomes  of  patients  after
AVI.
Recent publications  have  identiﬁed  a  number  of  baseline
ariables to  be  independently  associated  with  mortality  or
oor treatment  response  in  patients  undergoing  TAVI:  low
ody mass,  functional  status,  left  ventricular  dysfunction,
ow gradient  aortic  stenosis,  concentration  of  N-terminal
rohormone of  brain  natriuretic  peptide,  diabetes,  prior
troke, chronic  obstructive  pulmonary  disease,  chronic  kid-
ey disease,  severe  tricuspid  and  mitral  regurgitation  and
aseline anaemia  [1—9].  In  addition  to  baseline  demograph-
cs, anatomical  characteristics  may  also  help  to  predict
reatment response  after  TAVI.
natomical patient selection criteria
he  most  important  aspect  of  anatomical  screening  involves
ssessment of  the  arterial  vasculature  and  aortic  valvar  com-
lex  (left  ventricular  outﬂow  tract,  aortic  annulus,  sinus  of
alsalva, sinutubular  junction  and  ascending  aorta)  (Fig.  1).
his  information  will  guide  physicians  to  select  the  most
ppropriate access  route  (i.e.  transfemoral,  subclavian,
pical or  direct  aortic)  and  transcatheter  valve  size.  Fur-
hermore, it  will  alert  physicians  to  potential  complications
hat may  arise  during  the  procedure.  Information  about  spe-
iﬁc  anatomical  criteria  is  provided  in  the  paragraphs  that
ollow.
Patient  selection  for  TAVI  
Figure 1. After selecting the appropriate high or prohibitive sur-
gical  risk patient, it becomes critical to assess the anatomical
eligibility for transcatheter aortic valve implantation (TAVI). This
ﬁgure  demonstrates that every aspect of the vasculature from ‘‘skin
to  heart’’ needs to be examined with respect to minimal vessel
diameter, degree of atherosclerosis, tortuosity and calciﬁcation.
Furthermore, alternative access sites (e.g. subclavian, transapical
direct  aortic) should be assessed and kept in mind in case of bail
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SAPIEN XT  prostheses  are  6.0,  6.5  and  7.0  mm,  respec-out  options.
Assessment of the arterial vasculature
The  occurrence  of  vascular  complications  associated  with
TAVI is  not  surprising  given  the  use  of  large  bore
catheters and  imperfect  vascular  closure  devices.  Vascular
complications have  been  reported  in  2%  to  30%  of  patients
undergoing TAVI;  the  conﬂicting  reports  are  due  to  hetero-
geneous end-point  deﬁnitions  [10—13].
Peripheral  contrast  angiography  is  practical  and  asso-
ciated with  relatively  lower  costs,  lower  contrast  dye
injection and  lower  radiation  exposure  compared  with  MSCT
[14]. MSCT,  however,  provides  greater  appreciation  of  vessel
size,  tortuosity  and  calciﬁc  burden  [15].
A  recent  angiographical  study  identiﬁed  an  outer  sheath
diameter to  femoral  artery  minimal  luminal  diameter
t
t
Table  1 Diameters  of  the  eSheath  in  its  unexpanded  and  exp
Model Sheath ID
(unexpanded)
Sheath  OD
(unexpanded)
Sheath  OD
(expanded)
916ES23  16F  (5.3  mm)  6.7  mm  Up  to  8.9  mm  
918ES26  18F  (5.9  mm)  7.2  mm  Up  to  8.9  mm  
920ES29  20F  (6.7  mm)  8.0  mm  Up  to  9.9  mm  
ID: inner diameter; OD: outer diameter; THV: transcatheter heart valv
a Minimal vessel diameter requirement.167
SFAR)  ratio  greater  or  equal  to  1.05  as  a  predictor  of
alve Academic  Research  Consortium  (VARC)  major  vascu-
ar complications  as  well  as  30-day  mortality  [10].  The  SFAR
ut-off ratio  increased  to  1.10  in  the  absence  of  calcium  and
ecreased to  1.00  in  the  presence  of  calcium.  These  results
eed to  be  conﬁrmed  in  prospective  studies  and  should  also
nclude MSCT.
The femoral  artery  is  typically  used  as  the  default
ascular access.  Peripheral  vascular  disease  is  not  an  abso-
ute contraindication  to  TAVI;  it  does,  however,  increase
he risk  of  complications  signiﬁcantly.  Physicians  must  be
killed or  have  the  necessary  resources  to  treat  vascu-
ar injuries  (percutaneously  or  surgically).  Some  physicians
ttempt to  cautiously  advance  the  vascular  access  sheath
nd catheter  delivery  system  across  the  diseased  vascu-
ature, implant  the  valve  and  repair  any  complications
uch as  dissections  ‘‘on  the  way  out’’  by  percutaneous
ransluminal angioplasty/stent  implantation.  Alternatively,
eripheral vascular  interventions  (percutaneous  translumi-
al angioplasty  or  stent  implantation)  can  be  performed
rior to  valve  implantation.  While  this  latter  approach  has
een  performed  successfully  in  experienced  centres,  the  risk
f dislodging  the  implanted  stent  during  advancement  of
he vascular  access  sheath  or  delivery  catheter  needs  to  be
onsidered.
Signiﬁcant tortuosity  alone  of  the  iliofemoral  vessels
s not  necessarily  a  contraindication  to  TAVI  as  long  as
he vessels  are  otherwise  healthy  and  compliant  —– gentle
dvancement of  the  stiff  guidewire  or  vascular  access  sheath
ill tend  to  straighten  the  vessel.
The  Edwards  eSheath  features  the  innovative  ‘‘dynamic
xpansion mechanism’’  (DEM)  that  allows  for  transient
heath expansion  during  valve  delivery.  Immediately  after
he Edwards  SAPIEN  XT  prosthesis  passes  through  the  sheath,
he DEM  allows  the  sheath  to  return  to  a  low  proﬁle  diam-
ter. This  reduces  the  time  the  access  vessel  is  expanded,
hereby minimizing  the  risk  of  vascular  trauma.  The  unex-
anded eSheath  has  an  inner  diameter  of  5.3  mm  (16F)  and
n outer  diameter  of  6.7  mm  (20F)  for  implantation  of  the
3 mm  prosthesis;  an  inner  diameter  of  5.9  mm  (18F)  and  an
uter diameter  of  7.2  mm  (21—22F)  for  implantation  of  the
6 mm  prosthesis;  and  an  inner  diameter  of  6.7  mm  (20F)
nd an  outer  diameter  of  8  mm  (24F)  for  implantation  of  the
9 mm  prosthesis  (Table  1).  Acceptable  minimal  iliofemoral
iameters for  implantation  of  the  23,  26  and  29  mm  Edwardsively.
In the  current  version  of  the  Medtronic  CoreValve  sys-
em, a  custom  introducer  sheath  is  not  supplied.  Current
anded  state.
Loader  ID  Compatible  NovaFlex+
device
Minimum  vessel
diametera
21F  9355NF23  (23  mm  THV)  6.0  mm
21F  9355NF26  (26  mm  THV)  6.5  mm
23F  9355NF29  (29  mm  THV)  7.0  mm
e.
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Figure 2. Multislice computed tomography axial cuts of the aortic annulus from 12 patients, demonstrating that the aortic annulus is, in
fact, non-circular. The difference between the maximum and minimum diameter measurements of the aortic annulus is on average 6.5 mm
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aith a standard deviation of approximately 2 mm. The non-circular
n estimating the annulus diameter for transcatheter valve sizing.
ecommendations  are  to  use  a  Cook  30  cm  Check-Flo  Per-
ormer 18F  introducer  (Cook,  Bloomington,  IN,  USA).  The
t. Jude  30  cm  Ultimum  EV  18F  introducer  (St.  Jude,  Min-
etonka, MN,  USA)  is  less  utilized  because  it  has  less  column
trength and  is  therefore  less  kink  resistant  than  the  Cook
heath. The  acceptable  minimal  iliofemoral  diameter  for
mplantation of  the  26,  29  and  31  mm  Medtronic  CoreValve
rostheses is  6.0  mm.
Alternative routes  to  the  transfemoral  include  the
ubclavian artery  [16,17],  apex  of  the  heart  [18,19]
nd ascending  aorta  [20,21].  In  selected  cases,  non-
ransfemoral routes  may  be  safer  and  just  as  effective.
ransapical approaches  with  the  Edwards  SAPIEN  device,
enaValve and  Symetis  Acurate  system,  and  the  subcla-
ian and  direct  aortic  approaches  with  the  Medtronic
oreValve System  are  Conformité  Européenne  (CE)  mark
pproved.
[
t
c
f the aortic annulus limits applicability of two-dimensional imaging
The left  subclavian  artery  (as  opposed  to  the  right)  is
elected in  more  than  95%  of  Medtronic  CoreValve  subcla-
ian cases  [16].  In  most  cases,  the  approach  from  the  left
ubclavian is  straightforward  irrespective  of  the  aortic  root
ngulation. In  contrast,  if  the  angulation  between  the  plane
f the  annulus  and  a  horizontal  reference  line  is  more  than
0 degrees  (suggesting  a  horizontal  aorta  or  vertical  annu-
us plane),  an  approach  from  the  right  subclavian  will  be
echnically challenging  [22].  The  presence  of  an  internal
ammary coronary  artery  bypass  graft  is  a  relative  con-
raindication to  the  subclavian  approach.  Having  said  that,
uccessful cases  have  been  performed  in  its  presence  with
 minimum  vessel  diameter  requirement  of  6.5  to  7.0  mm
23]. In  order  to  reduce  the  risk  of  retrograde  dissection  of
he internal  mammary  artery  graft,  the  segment  of  the  sub-
lavian artery  proximal  to  the  internal  mammary  should  be
ree of  atherosclerotic  disease.
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C. Multislice computed tomography. D. Magnetic resonance imaging
Measurement of the aortic valve annulus
Surgeons  commonly  deﬁne  the  aortic  valve  annulus  as  the
semilunar crown-like  ring  demarcated  by  the  ‘‘draping’’
leaﬂet attachment  line  that  runs  across  the  aortic  root.
For the  purposes  of  TAVI,  the  enigmatic  ‘‘aortic  valve
annulus’’ corresponds  to  a  virtual  ring  formed  by  join-
ing the  basal  attachment  points  of  the  leaﬂets  within  the
left ventricle  [24].  This  plane  represents  the  inlet  from
the left  ventricular  outﬂow  tract  into  the  aortic  root.
The fact  that  the  aortic  valve  annulus  has  a  non-circular
shape has  led  to  a  great  deal  of  debate  over  the  opti-
mal imaging  modality  for  measuring  its  diameter  [25,26]
(Fig. 2).
The aortic  valve  annulus  diameter  can  be  measured  using
various imaging  modalities.  These  include  transthoracic
echocardiography (TTE),  transesophageal  echocardiography
(TEE), MSCT,  contrast  aortography  and  magnetic  resonance
imaging (Fig.  3).
Transcatheter aortic  bioprostheses  are  typically  over-
sized by  5  to  30%  relative  to  the  aortic  valve  annulus
diameter. The  intention  of  oversizing  is  to  create  enough
interference (or  radial  force)  between  the  prosthetic  valve
and aortic  valvar  complex  to  ensure  adequate  anchoring  and
sealing.
D
d
m
rameter of the aortic annulus. A. Echocardiography. B. Fluoroscopy.
According to  MSCT  data,  the  aortic  valve  annulus  is  non-
ircular in  the  vast  majority  of  patients  [25].  The  mean
ifference between  the  maximum  and  minimum  diameter
f the  aortic  annulus  is  6.5  mm  (95%  conﬁdence  interval,
.7—7.2) [26].  This  fact  explains  the  potential  shortcomings
f relying  on  two-dimensional  measurements  of  the  aortic
nnulus for  transcatheter  aortic  valve  sizing  (Fig.  4).
MSCT  multiplanar  reconstructions  (MPRs)  can  provide
oronal, sagittal  and  axial  images  of  the  aortic  root.  Method-
logies for  MPRs  of  the  aortic  valve  annulus  have  been
reviously described  [27].  In  the  axial  view,  the  aortic  valve
nnulus lies  at  a  level  just  below  the  basal  attachment  points
f the  three  leaﬂets  (Fig.  5).  From  this  view,  the  maximum
nd minimum  diameter,  perimeter  and  area  of  the  annulus
an be  measured  (Figs.  5B  and  6C).  The  maximum  and  mini-
um diameters  typically  correspond  to  coronal  and  sagittal
lanes cut  across  the  annulus,  respectively.  Depending  on
he orientation  of  the  chord  cut  across  the  annulus,  two-
imensional echocardiography  provides  a  ‘‘one-dimensional
iew’’ of  the  aortic  annular  dimensions;  typically  under-
stimating the  annulus  diameter  with  respect  to  MSCT.
espite this  knowledge,  we  are  still  left  with  the  conun-
rum of  how  to  appropriately  apply  MSCT  aortic  annular
easurements to  existing  echocardiographic  sizing  crite-
ia.
170  
Figure 4. Short-axis superior view of the human aortic valve seen
from  the ascending aorta. Depending on the orientation of the chord
transecting  the aortic annulus, and whether or not the chord tran-
sects  the centre of the aortic valve, different measurements of the
aortic  annulus can be made by two-dimensional imaging.
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Figure 5. Serial axial cuts across the aortic valvar complex. A. Basal att
0.85 mm) below the basal attachments of the aortic valvar leaﬂets and the
and minimum diameters are obtained whereas in (C), a tracing of the ‘
area measurements.
Figure 6. The Edwards SAPIEN XT valve is currently available in four s
ranging from 16 to 27 mm.N.  Piazza  et  al.
Aortography  during  preimplantation  balloon  aortic  valvu-
oplasty (i.e.  balloon  sizing)  is  a  simple  way  to  conﬁrm  the
ptimal valve  size  depending  on  the  presence  or  absence  of
ortic regurgitation  [28].
Having  said  all  of  this,  two-dimensional  echocardiography
TTE or  TEE)  remains  the  most  commonly  used  and  prac-
ical method  to  assess  the  aortic  valve  annulus  diameter.
onetheless, as  we  acquire  more  data  in  the  near  future,
SCT will  likely  become  the  primary  imaging  modality  to
easure the  dimensions  of  the  aortic  valvar  complex  and
uide transcatheter  aortic  valve  size  selection.
The  Edwards  SAPIEN  XT  THV  is  currently  available  in
our sizes  (20,  23,  26  and  29  mm)  and  can  be  implanted
n native  annuli  with  diameters  of  16  to  27  mm  (Fig.  6).
he CoreValve  is  currently  available  in  three  sizes  (26  mm,
9 mm  and  31  mm)  and  can  be  implanted  in  native  annuli
ith diameters  ranging  from  20  to  29  mm  (Fig.  7).
t’s not just about the aortic valve annular
easurements  —–  the aortic valvar complex
n  addition  to  the  aortic  annulus  diameter,  other  measure-
ents of  the  aortic  valvar  complex,  such  as  the  height
nd width  of  the  Sinus  of  Valsalva,  take-off  heights  of  the
oronary arteries,  left  ventricular  outﬂow  tract  diameter,
scending aorta  diameter  and  calciﬁcation  burden,  may
nﬂuence the  feasibility,  safety  and  effectiveness  of  the  pro-
edure (Table  2).
achments of the aortic valvar leaﬂets. B and C. Slice (approximately
 level at which the aortic annulus is measured. In (B), the maximum
‘aortic valve annulus’’ provides the perimeter and cross-sectional
izes (20, 23, 26 and 29 mm) and can treat aortic annuli diameters
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Figure 7. The Medtronic CoreValve is currently available in three sizes
from 20 to 29 mm.
Coronary artery disease
According  to  published  case  series,  up  to  three-quarters
of patients  undergoing  TAVI  may  have  documented  coro-
nary artery  disease.  Expectedly,  patients  with  coronary
artery disease  have  higher  surgical  risk  scores  and  associated
comorbidities than  patients  without  coronary  artery  disease
[29]. Percutaneous  coronary  intervention  in  association  with
TAVI has  been  reported  in  0  to  44%  of  patients.  Although
concomitant and  staged  strategies  have  been  reported  suc-
cessfully,  the  latter  approach  appears  to  be  more  commonly
used [30—34].  Discrepancies  exist  amongst  studies  as  to
whether coronary  artery  disease  negatively  impacts  survival
post-TAVI [30,35—37].  A  recent  study  showed  no  differences
Table  2  Medtronic  CoreValve  patient  evaluation
criteria.
Indications  for  26  mm  CoreValve
Annulus  diameter  20—23  mm
Ascending aorta  ≤  40  mm
Sinus  of  Valsalva  width  ≥  27  mm
Sinus  of  Valsalva  height ≥  15  mm
Indications  for  29  mm  CoreValve
Annulus  diameter  23—27  mm
Ascending aorta  ≤  43  mm
Sinus  of  Valsalva  width  ≥  29  mm
Sinus  of  Valsalva  height  ≥  15  mm
Indications  for  31  mm  CoreValve
Annulus  diameter  26—29  mm
Ascending aorta  ≤  43  mm
Sinus  of  Valsalva  width  ≥  29  mm
Sinus  of  Valsalva  height  ≥  15  mm
Vascular access diameter greater or equal to 6 mm for any valve
size.
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l (26, 29 and 31 mm) and can treat aortic annuli diameters ranging
n  VARC  clinical  outcomes  between  70  patients  who  under-
ent isolated  TAVI  versus  55  who  underwent  concomitant
AVI and  percutaneous  coronary  intervention  [38].
Optimal  management  of  patients  with  concomitant  coro-
ary artery  disease  undergoing  TAVI  is  currently  a  subject
f debate.  It  appears  that  a  staged  approach  (percuta-
eous coronary  intervention  followed  by  TAVI)  is  prudent
n patients  with  lesions  in  a  dominant  proximal  right  coro-
ary artery,  left  main,  proximal  left  anterior  descending  and
ominant proximal  circumﬂex  artery.
ranscatheter aortic valve implantation
TAVI)  in special subgroups
ailing surgical bioprosthetic valves
he  operative  mortality  for  elective  re-do  aortic  valve
urgery is  reported  to  range  from  2  to  7%;  but  this  percentage
an increase  to  more  than  30%  in  high-risk  and  non-elective
atients [39—41].  Understanding  the  basic  construction
nd dimensions,  radiographic  identiﬁcation  and  potential
ailure modes  of  surgical  aortic  valve  bioprostheses  is  fun-
amental for  understanding  the  key  principles  involved  in
ranscatheter aortic  valve-in-surgical  aortic  valve  (TAV-in-
AV) implantation  [42].  One  important  fact  is  that  the
abelling size  of  surgical  bioprostheses  does  not  correspond
o their  internal  stent  diameter;  the  internal  stent  diameter
etermines the  transcatheter  aortic  valve  size.  Reference
ables relating  labelling  sizes  and  internal  stent  diameters
ave already  been  published  [42].  Over  100  successful  TAV-
n-SAV implantations  have  been  reported  with  the  Medtronic
oreValve and  Edwards  SAPIEN  transcatheter  heart  valve
or failing  stented  and  stentless  surgical  bioprostheses  [43].
ransaortic valvular  gradients  after  TAV-in-SAV  implantation
re around  20  mmHg  (higher  than  TAVI  for  native  aortic  valve
tenosis or  surgical  aortic  valve  replacement)  and  paravalvu-
ar leaks  are  typically  trivial  to  mild.
1B
A
s
s
A
l
t
a
a
s
L
T
c
n
r
i
4
u
i
a
T
t
A
A
e
w
r
D
N
C
C
R
[
[
[
[
[
[
[
[
[
[
[
[
[72  
icuspid valves
lthough  congenital  or  acquired  bicuspid  aortic  valve
tenosis is  considered  a  contraindication  to  TAVI,  several
uccessful case  reports  have  been  documented  [44—51].
necdotally, stenotic  bicuspid  aortic  annuli  are  usually
arger and  more  eccentric  than  stenotic  tricuspid  aor-
ic valves.  As  such,  three-dimensional  imaging  is  strongly
dvised for  transcatheter  aortic  valve  sizing.  Furthermore,
ssessment of  the  ascending  aorta  and  its  treatment  require
pecial attention.
ower surgical risk patients
AVI  was  initially  conceived  for  the  treatment  of  high  surgi-
al risk  or  inoperable  patients.  A  recent  observational  report
oted  a  paradigm  shift  toward  the  selection  of  lower  surgical
isk patients  for  TAVI.  Furthermore,  signiﬁcantly  better  clin-
cal outcomes  were  observed  in  the  lower  (mean  STS  score
%) than  higher  (mean  STS  score  7%)  surgical  risk  patients
ndergoing TAVI,  at  30-day  and  6-month  follow-up  [52].  With
ncreasing volumes  and  continued  encouraging  results,  it
ppears that  lower  surgical  risk  patients  are  receiving  TAVI.
his is  further  corroborated  by  the  ongoing  preparation  of
he SURgical  aortic  valve  replacement  versus  Transcatheter
ortic Valve  Implantation  (SURTAVI)  trial  and  Placement  of
oRTic traNscathetER  (PARTNER  II)  valve  trial,  which  are
xpected to  randomize  intermediate  surgical  risk  patients
ith an  STS  score  of  4  to  8%  to  TAVI  or  surgical  aortic  valve
eplacement.
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